Evidence map›Paper›PMID 7474082›Full record

ArticleJournal of virology1995

The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis.

A Henke, S Huber, A Stelzner, J L Whitton

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 262 citations in OpenAlex.

  1. Brazilian Society of Cardiology Guideline on Myocarditis - 2022.Arquivos brasileiros de cardiologia · 2022
    Guideline
  2. Pooled it
  3. Cardiomyocyte β-arrestins mediate inflammation and cGAS-STING activation in CVB3 viral myocarditis.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. A viral-specific CD4Frontiers in immunology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection.Translational research : the journal of laboratory and clinical medicine · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A HenkeDepartment of Neuropharmacology, Scripps Research Institute, La Jolla, California 92037, USA.
S Huber
A Stelzner
J L Whitton
Scripps Research Institute · US

Funding

CYTOTOXIC T-CELL RESPONSES TO VIRUS INFECTIONR01AI027028 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WHITTON, J. LINDSAY · 1989 to 2008
$3.5M
ANALYSES OF CYTOTOXIC T CELL RESPONSE TO VIRUS INFECTIONR21AI027028 · NIAID · SCRIPPS RESEARCH INSTITUTE · PI WHITTON, J. LINDSAY · 1999 to 1999
–
NIAID NIH HHS AI-27028
6 · The paper itself

Abstract

Coxsackievirus infections have previously been shown to cause acute or chronic myocarditis in humans, and several mouse models have been established to study the pathology of this disease. Myocardial injury may result from direct viral effects and/or may be immune mediated. To determine the relative roles of these processes in pathogenesis, we have compared coxsackievirus B3 (CVB3) infections of normal and immuno-compromised transgenic knockout (ko) mice. CVB3 was able to infect all strains used (C57BL/6, CD4ko, and beta-microglobulin ko [beta 2Mko]), and following intraperitoneal injection, two disease processes could be distinguished. First, the virus caused early (3 to 7 days postinfection) death in a viral dose-dependent manner. Immunocompetent C57BL/6 mice were highly susceptible (50% lethal dose = 70 PFU), while immunodeficient transgenic ko mice were less susceptible, showing 10- and 180-fold increases in the 50% lethal dose (for CD4ko and beta 2Mko mice, respectively). Second, a histologic examination of surviving CD4ko mice at 7 days postinfection revealed severe myocarditis; the inflammatory infiltrate comprised 40 to 50% macrophages, 30 to 40% NK cells, and 10 to 20% CD8+ T lymphocytes. The infiltration resolved over the following 2 to 3 weeks, with resultant myocardial fibrosis. In vivo depletion of CD8+ T lymphocytes from these CD4ko mice led to a marked reduction in myocarditis and an increase in myocardial virus titers. beta 2Mko mice, which lack antiviral CD8+ T cells, are much less susceptible to early death and to the development of myocarditis. We conclude that our data support a strong immunopathologic component in CVB3-induced disease and implicate both CD4+ and CD8+ T cells. Compared with immunocompetent animals, (i) mice lacking CD4+ T cells (CD4ko) were more resistant to virus challenge, and (ii) mice lacking CD8+ T cells (beta 2Mko and in vivo-depleted CD4ko) showed enhanced survival and a reduced incidence of the later myocarditis. Nevertheless, the picture is complex, since (iii) removal of the CD4+ component, while protecting against early death, greatly magnified the severity of myocarditis, and (iv) removal of the CD8+ cells from CD4ko mice, although protecting against early death and later myocarditis, led to markedly increased virus titers in the heart. These data underscore the complex balance between the costs and benefits of effective antiviral immune responses.

Indexed as

Enterovirus B, HumanAnimalsAntibodies, ViralApoptosisCD8-Positive T-LymphocytesCoxsackievirus InfectionsHeartImmunohistochemistryLymphocyte DepletionMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMyocarditisMyocardiumAntibodies, ViralTumor Necrosis Factor-alpha

Identifiers

PMID7474082
PMCPMC189582
OpenAlexW2102196716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.